Drug insight: Existing and emerging therapies for osteoporosis.
Osteoporosis is a major public health problem that is characterized by microarchitectural deterioration, low bone mass, and increased risk of fractures. Currently, many women and men affected with this disease are not diagnosed or treated. As osteoporosis is often clinically silent, risk-factor assessment and measurement of BMD are needed to identify those who may benefit from osteoporosis therapy. Although adequate daily intake of calcium and vitamin D, and regular weight-bearing exercise are important for skeletal health, they are not adequate treatments for individuals with osteoporosis. Therapies approved for treatment and/or prevention of osteoporosis in the United States include oral bisphosphonates (alendronate, ibandronate and risedronate), calcitonin, estrogens, teriparatide (parathyroid hormone fragment [1-34]), and raloxifene. For most patients, oral bisphosphonates are the treatment of choice, given the large-scale randomized-trial data demonstrating efficacy in fracture reduction, although bisphosphonates that reduce spine and nonspine fractures (e.g. alendronate and risedronate) are preferred. For high-risk patients (those with very low bone density, or with fractures), teriparatide therapy for 2 years should be considered. The treatment paradigm for osteoporosis will evolve further as promising new treatments progress through clinical development.
Mulder
Jean E
JE
Harvard Medical School, and Brigham and Women's Hospital, Boston, MA 02115, USA. jmulder@partners.org
Kolatkar
Nikheel S
NS
LeBoff
Meryl S
MS
D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D002116:Calcitonin / Q000627:therapeutic use; D002118:Calcium / Q000502:physiology; D004164:Diphosphonates / Q000627:therapeutic use; D004358:Drug Therapy / Q000639:trends*; D004359:Drug Therapy, Combination; D020249:Hormone Replacement Therapy / Q000379:methods; D006801:Humans; D010024:Osteoporosis / Q000188:drug therapy*; D010281:Parathyroid Hormone / Q000502:physiology; D011960:Receptors, Estrogen / Q000819:agonists; D014807:Vitamin D / Q000502:physiology
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D010281:Parathyroid Hormone; D011960:Receptors, Estrogen; D014807:Vitamin D; D002116:Calcitonin; D002118:Calcium